Podcasts about new advances

Cancer has long been associated with aging, but in recent years, doctors have seen an alarming rise in colorectal cancer and other cancers among younger adults. In this episode of Health Matters, host Courtney Allison speaks with Dr. Dorna Jafari, chief of colorectal surgery at NewYork-Presbyterian Brooklyn Methodist Hospital, about what may be contributing to this growing public health concern. Dr. Jafari explains that colorectal cancer is now the leading cause of cancer death in people under age 50 and discusses the "birth cohort effect" researchers have identified among people born after 1960. She explores several factors that may be influencing cancer risk, including changes in diet, increased consumption of ultra-processed foods, disruptions to the gut microbiome, antibiotic exposure, and the growing presence of microplastics in the environment. The conversation also focuses on prevention. Dr. Jafari shares practical steps people can take to support a healthy microbiome and reduce cancer risk, including increasing fiber intake, staying physically active, limiting sugary beverages, and making realistic lifestyle changes over time. Finally, she discusses the exciting advances changing the future of oncology. From targeted cancer therapies and immunotherapy to AI-assisted diagnosis and improved screening tools, Dr. Jafari explains why cancer outcomes continue to improve and why early detection remains one of the most powerful tools available—especially when it comes to colorectal cancer screening. Chapters 00:00 – Why Are More Young People Getting Cancer? Understanding the rise of early-onset cancers and why colorectal cancer rates are increasing in adults under 50 03:15 – Diet, Microbiome, and Environmental Risks How ultra-processed foods, sugary drinks, antibiotics, and microplastics may influence cancer risk 07:20 – New Advances in Cancer Treatment The shift toward targeted therapies, immunotherapy, AI, and personalized cancer care 10:15 – Screening, Prevention, and Living Healthier Why colonoscopies remain the gold standard and the lifestyle habits that can help lower risk Key Topics Covered Early-onset colorectal cancer Rising cancer rates in young adults Colorectal cancer mortality trends Ultra-processed foods and cancer risk Sugar-sweetened beverages Gut microbiome health Antibiotic exposure and cancer Microplastics and potential health effects Fiber and digestive health Cancer prevention strategies Targeted cancer therapies Immunotherapy Artificial intelligence in oncology Colonoscopy screening Blood-based cancer screening tests Fertility preservation during cancer treatment Holistic cancer care Cancer survivorship and outcomes Key Takeaway While cancer is increasingly affecting younger adults, there are meaningful steps people can take to reduce their risk. Prioritizing screening, maintaining a healthy diet rich in fiber, limiting ultra-processed foods and sugary drinks, staying active, and paying attention to symptoms can make a difference. At the same time, advances in targeted therapies, immunotherapy, and AI-driven diagnostics are helping improve outcomes and offering new hope for the future of cancer care. Doctor Bio Dr. Mehraneh Dorna Jafari is chief of colorectal surgery at NewYork-Presbyterian Brooklyn Methodist Hospital and associate professor of surgery at Weill Cornell Medicine. She is the director of clinical research in the department of surgery at NewYork-Presbyterian/Weill Cornell Medical Center. She is board-certified in general surgery and colon and rectal surgery. Dr. Jafari specializes in the comprehensive care of colorectal cancer patients, patients with peritoneal surface disease as well as those patients with benign colorectal disease. Dr Jafari works with a world-renowned group of multidisciplinary specialists to help promote a patient centered treatment plan for her patients, including radiation oncologists, medical oncologists, radiologists, pathologists, gastroenterologists, and interventional radiologists. Her goal is to provide precision medicine to patients that is safe and effective. Dr. Jafari has expertise in minimal access techniques, including laparoscopic, and robotic surgery. In addition, she has special interests in sphincter preserving surgery (helping rectal cancer patients avoid a permanent ostomy), maintaining fertility in cancer patients, and improving quality of life and bowel function after rectal surgery.  Dr Jafari has been at forefront of research with regards to improving outcomes using enhanced recovery and narcotic sparing protocols. Dr. Jafari is among a small number of surgeons who offers surgery for metastatic colon, appendiceal and peritoneal surface disease. She utilizes cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), which involves heated chemotherapy applied directly within the abdominal cavity following removal of cancerous tumors. Dr. Jafari's clinical research focuses on quality of life and oncological outcomes for colorectal cancer patients. Her main area of expertise is starting chemotherapy earlier in cancer treatment to allow patients to recover their quality of life sooner. Dr. Jafari has written extensively and published in many major journals, including the Journal of the American Medical Association (JAMA), Annals of Surgery, and the Journal of the American College of Surgeons. She has led numerable courses teaching surgeons around the country how to perform minimal invasive surgery. Dr. Jafari is actively involved in many national surgical and oncologic societies, including the American College of Surgeons, Society of Surgical Oncologists, American Society of Colon and Rectal Surgeons and Association of Women Surgeons.

The Snowbirds, Canada's iconic acrobatic flying team, is headed for its final landing. Its jets are so old there are no spare parts and they're becoming unsafe. Ottawa says new planes are being ordered, but it's suspending operations in the meantime. Some say that long pause could make it impossible to start up again.Also: More and more mosquitoes are exposing Canadians to deadly diseases. Thank the warming climate for that. Some experts say there may be a case for trying to wipe out the entire species.And: The good news about cancer is that two new drugs are making inroads on prevention and treatment. One of them is familiar; it's GLP-1, also known as Ozempic.Plus: Fire breaks are usually chunks of forest chopped down to stop wildfires from threatening populated areas. But in the Northwest Territories, people are experimenting with using them for things like garden patches and skating rinks.

Send us Fan Mail

In the season two premiere episode of Thinking Thoracic, cohosts Drs. Erin Gillaspie, Hari Keshava, Jeff Yang, and Jane Yanagawa review the latest thoracic surgery research presented at the 2026 STS Annual Meeting in New Orleans.

Dr. Cedrek McFadden breaks down progress being made in colorectal cancer detection and treatment. Also, three inspiring women entrepreneurs share their stories. Plus, Cazzie David joins to talk about her new book ‘Delusions: Of Grandeur, of Romance, of Progress,' sharing personal stories and reflections ahead of her 30th birthday. And, bestselling author Myka Meier shares lessons on resetting kindness. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

UAP Tracking technology is finally here. In this episode, we reveal the hard science behind UFO detection and the new sensor systems designed to capture UAP data In this episode, Matt sits down with Reed Summers and Rich Hoffman to break down the groundbreaking developments that will be revealed at the upcoming UAP Tracking Summit. We explore the specific technologies being deployed to detect and track Unidentified Anomalous Phenomena in our airspace. From new radar systems to coordinated citizen science data, learn how the scientific community is building the ultimate "UAP Trap."  This summit includes Congressman Eric Burlison, Dr. Garry Nolan, Dr. Beatriz Villarroel, Richard Dolan, Ryan Graves, and the field work of John and Jerry Tedesco.Join the two day UAP Summit: https://uapsummit.org/Become a supporter of this podcast: https://www.spreaker.com/podcast/the-good-trouble-show-ufo-uap-politics-interviews--5808897/support.Sponsorship Inquires:  sponsors@thegoodtroubleshow.comSubstack:  https://substack.com/@thegoodtroubleshowLinktree: https://linktr.ee/thegoodtroubleshowPatreon: https://www.patreon.com/TheGoodTroubleShowYouTube: https://www.youtube.com/@TheGoodTroubleShowTwitter: https://twitter.com/GoodTroubleShowInstagram: https://www.instagram.com/thegoodtroubleshow/TikTok: https://www.tiktok.com/@goodtroubleshowFacebook: https://www.facebook.com/The-Good-Trouble-Show-With-Matt-Ford-106009712211646Threads: @TheGoodTroubleShowBlueSky: @TheGoodTroubleShow

In this episode, we'll break down the Trump administration's new licensing agreement with Nvidia and AMD for semiconductor exports and what this development means for U.S. national security (00:35), explore concerns about an AI-driven economic bubble (22:17), and unpack recent advancements for the federal government's adoption AI after the U.S. General Services Administration approved OpenAI, Anthropic, and Google as vendors (37:18).

Pacific Northwest National Laboratory has developed a contactless system to detect fentanyl and other opioids in real time on site. By eliminating the need to send samples to a lab and wait for test results, this technology has the potential to transform security screening for cargo, baggage, mail and even people. Here with more on the process and its implications is senior technical advisor in the National Security Directorate at Pacific Northwest National Laboratory, Kristin Omberg.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Speaker: Prof William Sellers, Broad Institute Harvard

In today's episode of The Root Cause Medicine Podcast, Dr. Kate Kresge sits down with Dr. Eve Henry to explore the often-misunderstood world of cholesterol, lipids, and heart disease risk. You'll hear them discuss: 1. Why cholesterol matters for longevity and heart health 2. Advanced lipid testing beyond standard panels 3. How to interpret ApoB, LP(a), and triglyceride levels 4. Understanding medications, supplements, and lifestyle approaches for heart health Dr. Eve Henry is board certified in Internal and Integrative Medicine. With extensive experience in personalized medicine and longevity science, she is dedicated to providing innovative care that optimizes healthspan and lifespan. She was previously Medical Director at Early Medical and is now founder of her own clinic, Eve Henry MD. She also serves as Medical Advisor to multiple start ups and enjoys her work educating leadership teams and consumers on ways to enhance their own health.

Paper checks remain a popular payment method in the U.S., despite skyrocketing fraud rates and safer digital alternatives like Zelle, PayPal, and Bitcoin. As criminals exploit vulnerabilities like mailbox theft and check washing, it's time to embrace 21st-century payment methods. And Ric discusses the latest in Alzheimer's drug treatments and lower cost blood test with Mark Roithmayr. He's the CEO of the Alzheimer's Drug Discovery Foundation, a trailblazer in Alzheimer's research and funding. #CheckFraud #DigitalPayments #StopWritingChecks #BankingSecurity #Bitcoin #Zelle #Venmo #FinancialTips #FraudPrevention #ModernFinance#Al zheimersBreakthrough #ADDF #CognitiveHealth #Biogen #Lilly #DementiaCare #BloodTestInnovation #AffordableDiagnostics #NeuroScience #NewEraInMedicine ----- Join our mailing list: https://www.thetayf.com/pages/podcast Subscribe to podcast updates: https://form.jotform.com/223614751580152  Ask Ric: https://www.thetayf.com/pages/ask-ric  -----   Links from today's show:   Ric's #1 Bestseller - The Truth About Crypto:   https://www.amazon.com/Truth-About-Crypto-Easy-Understand/dp/1668002329/ Alzheimer's Drug Discovery Foundation: https://www.alzdiscovery.org/ 12/9 Webinar - What the Election Results Mean for Crypto: https://dacfp.com/events/what-the-election-results-mean-for-crypto 12/10 Webinar - The Retirement Revolution: ETF Solutions for Modern Retirement Planning: https://www.thetayf.com/pages/the-retirement-revolution-etf-solutions-for-modern-retirement-planning 2/24-2/26 Wealth Management Convergence-2025 https://www.thetayf.com/pages/convergence-2025 11/13 Webinar Replay - An Innovative Way to Generate Income in a World of Declining Rates: https://www.thetayf.com/pages/november-13-2024-an-innovative-way-to-generate-income 10/9 Webinar Replay - Crypto for RIAs: Yield, Staking, Lending and Custody. What's beyond the ETFs? https://dacfp.com/events/crypto-for-rias-yield-staking-lending-and-custody-whats-beyond-the-etfs/ -----   Follow Ric on social media:   Facebook: https://www.facebook.com/RicEdelman Instagram: https://www.instagram.com/ric_edelman/ LinkedIn: https://www.linkedin.com/in/ricedelman/ X: https://twitter.com/ricedelman YouTube: https://www.youtube.com/@RicEdelman -----   Brought to you by:   Invesco QQQ: https://www.invesco.com/qqq-etf/en/home.html State Street Global Advisors: https://www.ssga.com/us/en/intermediary/etfs/capabilities/spdr-core-equity-etfs/spy-sp-500/cornerstones Schwab: https://www.schwab.com/ TAYF Disclosure page: https://www.thetayf.com/pages/sponsorship-disclosure-fee

SLEERICKETS is a podcast about poetry and other intractable problems. My book Midlife now exists. Buy it here, or leave it a rating here or hereFor more SLEERICKETS, check out the SECRET SHOW and join the group chatLeave the show a rating here (actually, just do it on your phone, it's easier). Thanks!Wear SLEERICKETS t-shirts and hoodies. They look good!SLEERICKETS is now on YouTube!Some of the topics mentioned in this episode:– The Promise of Words by Laura Riding– Elijah's notes on the essay– Beyond Poetry by Blake Smith– The Republic by Plato– On Portents by Robert Graves– No Second Troy by W. B. Yeats– Versecraft on Riding & Graves, on John Martin Finlay, on CameronFrequently mentioned names:– Joshua Mehigan– Shane McCrae– A. E. Stallings– Ryan Wilson– Morri Creech– Austin Allen– Jonathan Farmer– Zara Raab– Amit Majmudar– Ethan McGuire– Coleman Glenn– Chris Childers– Alexis Sears– JP Gritton– Alex Pepple– Ernie Hilbert– Joanna PearsonOther Ratbag Poetry Pods:Poetry Says by Alice AllanI Hate Matt Wall by Matt WallVersecraft by Elijah BlumovRatbag Poetics By David Jalal MotamedAlice: Poetry SaysBrian: @BPlatzerCameron: CameronWTC [at] hotmail [dot] comMatthew: sleerickets [at] gmail [dot] comMusic by ETRNLArt by Daniel Alexander Smith

Paul Byrne talks to Ann Murphy on the remains of an unidentified man found along the River Lee in 1999 Hosted on Acast. See acast.com/privacy for more information.

Episode Overview:In this episode, Kate and Sam dive into a discussion of how they're using AI in business as a tool for organisation, strategy, and even as a coaching assistant. They discuss some of the most recent AI developments that are impacting businesses in previously unimaginable ways. They discuss the continuing implications of AI-generated content, how it can be embraced positively, and the importance of discernment in the digital age.Key Takeaways:1. Using AI to Help with Overwhelm and Task Management: Sam discusses her feelings of overwhelm due to numerous unfinished tasks and the need for better prioritisation. Kate and Sam discuss how they're using AI to help organise tasks and set priorities, and using AI as a personal assistant.2. The Future of Coaching with AI: Kate and Sam discuss new coaching bots that are being embraced by some coaches. They discuss how, like in all other industries, coaches should not feel threatened by AI, but rather embrace it as a value-add.3. The Evolution of Podcasting with AI: Kate discusses a new AI-tool she came across that creates engaging podcasts based on existing content, highlighting the rapid advancements in AI.4. Challenges of Trust and Authenticity in a Digital World: The hosts discuss their concerns about the potential for AI to create content that blurs the lines between reality and fabrication. It highlights the importance of critical thinking and discernment, especially for younger generations consuming content online.5. The Role of Human Experience: Kate and Sam reflect on how AI, while powerful, cannot fully replicate human understanding and emotional intelligence. Both share insights from their children about the challenges of navigating truth in an age of misinformation.Subscribe to our podcast for more discussions on business, motherhood, and the impact of technology!Connect with the Hosts:Kate De Jong, PhD | Inspired BusinessWebsite: https://katedejong.com/Instagram: katedejong.inspiredbusinessEmail: kate@katedejong.comSam Morris | The Business ImplementorWebsite: https://thebusinessimplementor.com/Instagram: sammorris.businesscoachEmail: sam@thebusinessimplementor.com

In this informative episode of Bladder Cancer Matters, host Rick Bangs welcomes back Dr. Ashish Kamat, an expert in urology and bladder cancer research from MD Anderson Cancer Center. They dive into the latest updates on BCG (Bacillus Calmette-Guérin) and its crucial role in treating non-muscle invasive bladder cancer. Dr. Kamat provides an insightful overview of BCG's effectiveness, the current shortage, and emerging alternatives. He explains the factors behind the supply issues and how treatments such as reduced dosages and novel combinations like gemcitabine and docetaxel are helping to bridge the gap. Listeners will also hear about promising new therapies on the horizon, including gene therapy with Adstiladrin, Pembrolizumab, and ANKTIVA's combination with BCG. Dr. Kamat sheds light on how these advancements could change the landscape of bladder cancer treatment while emphasizing the importance of tailored care and shared decision-making for each patient. This episode is a must-listen for those affected by bladder cancer and anyone interested in the latest medical developments in this field.

Featuring perspectives from Dr Rafael Fonseca, Dr María-Victoria Mateos and Dr Elizabeth O'Donnell, moderated by Dr O'Donnell, including the following topics: Introduction (0:00) Treatment Approaches for Newly Diagnosed Multiple Myeloma (MM) — Dr Fonseca (2:05) Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies in the Care of Patients with MM — Dr Mateos (22:06) Incorporation of Other Novel Agents and Strategies into the Management of Relapsed/Refractory MM — Dr O'Donnell (39:25) CME information and select publications

Luke O'Neill joins Pat to discuss three different stories this week focusing on advances in brain research, including an AI map of the brain and what it can do.

This episode is part of our oncology mini-series on VETchat by The Webinar Vet. Joining Anthony today is Owen Davies, RCVS, American and European specialist in veterinary oncology. In this episode, Anthony and Owen discuss some of the new advancements in oncology. Owen starts by sharing his career to date and then discusses some of the most recent advancements in oncology, such as those in screening tests and osteosarcoma treatment. They also talk about the use of liquid biopsies for early cancer detection, the challenges of treating feline lymphoma, and the potential of immunotherapy in cancer treatment.

For over a century, different surgical interventions have been explored to address symptoms of Parkinson's disease, and researchers are continuing to innovate and improve surgical treatments today. With new technology and an ever-expanding understanding of the function of the nervous system and the pathophysiology of Parkinson's disease, neurosurgical interventions are becoming more effective and more personalized. Dr. Doris Wang joins us in this episode to discuss her work using focused ultrasound and deep brain stimulation (DBS) as treatments for Parkinson's disease and other movement disorders. She discusses some of the benefits and limitations of focused ultrasound treatment, comparisons of traditional versus asleep interventional MRI-guided deep brain stimulation surgery, advances in adaptive deep brain stimulation, and the development of gait-related biomarkers that could drive adaptive DBS. Doris is a neurosurgeon and Associate Professor in the Department of Neurological Surgery at the University of California, San Francisco (UCSF). This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

For over a century, different surgical interventions have been explored to address symptoms of Parkinson's disease, and researchers are continuing to innovate and improve surgical treatments today. With new technology and an ever-expanding understanding of the function of the nervous system and the pathophysiology of Parkinson's disease, neurosurgical interventions are becoming more effective and more personalized. Dr. Doris Wang joins us in this episode to discuss her work using focused ultrasound and deep brain stimulation (DBS) as treatments for Parkinson's disease and other movement disorders. She discusses some of the benefits and limitations of focused ultrasound treatment, comparisons of traditional versus asleep interventional MRI-guided deep brain stimulation surgery, advances in adaptive deep brain stimulation, and the development of gait-related biomarkers that could drive adaptive DBS. Doris is a neurosurgeon and Associate Professor in the Department of Neurological Surgery at the University of California, San Francisco (UCSF). This podcast is geared toward researchers and clinicians. If you live with Parkinson's or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson's Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

03-18-2024 J.L. Hancock Learn more about the interview and get additional links here: https://thedailyblaze.com/from-swarms-to-swarming-shocking-new-advances-in-warfare/ Subscribe to the best of our content here: https://priceofbusiness.substack.com/ Subscribe to our YouTube channel here: https://www.youtube.com/channel/UCywgbHv7dpiBG2Qswr_ceEQ

AI is enabling new strides in autonomous driving. In this episode, Azeem Azhar joins the co-founder and CEO of Wayve, Alex Kendall, to explore how the AI revolution is opening new market opportunities for the auto industry. Wayve is a UK-based start-up that makes AI technology for self-driving vehicles.

If you think you know all about the capabilities of drones, you don't know the half of it. In this podcast we explore the capabilities of drones to fly “inside of buildings” and not using GPS. My guest is Blake Resnick a technology star if there ever was one. We talk about the future of drone technology and the expected revisions to FAA rules and regulations which will open up the use of drones in so many different ways. We also do a deeper dive into his company BRINC and what their drones can do for public safety agencies. It is a very positive application of the technology.This episode is sponsored by AshBritt, a national rapid-response emergency management and logistics company. Celebrating its 30th year, AshBritt has led response efforts following 60 federally declared disasters across 30 states and has conducted more than 400 missions, successfully serving over 600 clients. AshBritt is the trusted emergency management contractor for cities, counties, states and for federal agencies, including the Department of Defense where AshBritt holds a pre-position debris management contract which covers 25 U.S. states.  Eric Holdeman is a professional emergency manager who is passionate about providing information that can help families, businesses & governments become better prepared for disasters of all types. Hear first hand expert insights from Eric on his Podcast, Blog & EricHoldeman.com.

Technology correspondent Paul Matthews joins Kathryn to look at some of the latest impressive advances brought to market in the last few years - including "electronic skin", storing energy as heat in a "sand battery" and biological storage. He'll also look at how Meta's Threads is going, one week on - how many users does it have and how's the feedback been? And as is often the way during tough economic times, there are also bargains to be had and many have come knocking on the door of Kiwi tech companies looking to make an acquisition. Paul is chief executive of CIO Studio.

Today we have our good friend and colleague Dr. Dominic D'Agostino returning for his third appearance on STEM-Talk. Dom, as most of our longtime listeners know, is well-known for his research into the ketogenic diet and the physiological benefits of nutritional ketosis. Since our last conversation with Dom in 2019, a tremendous body of research has been added to the literature about the therapeutic potential of ketosis. The high-fat, low-carb ketogenic diet has been linked to advances in the treatment of Alzheimer's, cancer, migraines, type-2 diabetes, psoriasis, sleep apnea, psychiatric disorders, traumatic brain injuries as well as a host of other diseases and disorders, which we cover in today's interview. In episode 14 of STEM-Talk, we talked to Dom about his development and testing of metabolic therapies involving the ketogenic diet for a wide range of diseases and conditions. In episode 87, Dom returned to reflect on his 10 years of research focused on the high-fat/low-carbohydrate diet. In today's interview, we talk to Dom about this latest work as well as his extensive research on hyperbaric oxygen. Dom is a tenured Associate Professor in the Department of Molecular Pharmacology and Physiology at the University of South Florida Morsani. He specializes in neuroscience, molecular pharmacology, nutrition, and physiology. Dom also is our colleague and a research scientist here at the IHMC. Show notes  [00:02:50] Dawn opens the interview mentioning Dom's recent IHMC Evening Lecture, in which he mentions the film “First Do No Harm” starring Meryl Streep. The film is based on the true story of a four-year-old boy diagnosed with severe epilepsy, whose extreme seizures continued despite extensive medical treatments. The boy's mother reached to Dr. John Freeman, a physician who had successfully treated patients with a ketogenic diet. Dawn asks Dom to give some context about this fictional film based on a true story. [00:05:05] Dawn asks Dom to discuss the many evidence-based applications of the ketogenic diet that he highlighted in his IHMC evening lecture. [00:07:11] Ken asks Dom about another story involving Russell Winwood, a man with severe chronic obstructive pulmonary disease, also known as COPD. Russell reached out to Dom with respect to treating his COPD with a ketogenic diet. [00:11:21] Ken asks if Russell only engaged in the ketogenic diet or if also used exogenous ketones. [00:12:10] Ken mentions that the ketogenic diet has the broad potential to be an anti-inflammatory diet. Ken goes on to mention that COPD is an inflammatory disease. As Dom's case report suggested, Ken wonders if the ketogenic diet has the potential to have strong therapeutic effects for other inflammatory conditions as well. Ken asks what other conditions Dom thinks might benefit from therapeutic ketosis. [00:14:02] Dawn mentions that Dom has been busy since his last appearance on STEM-Talk, having authored or collaborated on more than 40 papers, one of which garnered a lot of attention and was published in Frontiers in Neuroscience. This paper investigated whether therapeutic ketosis via ketone esters could represent a viable way to treat epilepsy and other seizure disorders. Dawn asks Dom to elaborate on this paper's findings and their significance. [00:16:26] Ken mentions that those listeners who are unfamiliar with ketone esters may want to check out our interview with Dr. Brianna Stubbs. Ken asks Dom to give a quick primer on ketone esters and why so many researchers in the field are excited about their potential. [00:19:20] Ken mentions that in addition to ketone salts and ketone esters, there are other product formulations out now, like the one from a company called Kenetik. Ken asks Dom what he thinks about this formulation. [00:23:33] Dawn mentions that Dom has had a number of animal studies published since 2019 looking at ketone induced neuroprotection and asks Dom to give an overview of some of this...

Shereen Siewert welcomes Paul Thomas, a professor in the Department of Physics and Astronomy at the University of Wisconsin – Eau Claire, and Wausau School District Planetarium Director Chris Janssen to discuss the latest in space exploration news and a preview of what to expect in the year ahead.

Merry Christmas to all of you Christmas-goers out there! Can you believe this is the last episode of According to RP for 2022? Thank you to all of our guests and supporters for a fantastic year! According to RP will be back in 2023! December is AIDS awareness month. With the world's focus being on COVID-19, many have forgotten that we have and still are fighting other healthcare crises. HIV/AIDS is one of them. In this episode, RP is chatting with the fabulous Dr. Cassandra Esperant, PharmD, AAHIVP. Dr. Esperant focuses on HIV prevention. Tune in as she talks about how HIV/ AIDS is still rampant, new advances in the prevention and maintenance of the disease, and hope for a future without HIV/ AIDS. To learn more about Dr. Cassandra and her amazing work. Follow her on Instagram @theprepandhivpharmacist and LinkedIn at Cassandra Esperant, PharmD, AAHIVP According to RP can be accessed everywhere you enjoy your podcasts!

2 part session: Join the following three physicians as they discuss new advances in treatment of uveal melanoma of the eye. This session was sponsored in part by Aura Biosciences. They discuss the following:  -RADIATION RETINOPATHY -Pars plana vitrectomy (PPV) with diode -ENDORESECTION -ADVANCES IN TREATMENT OF THE EYE (Aura presentation) Dr. Scott Walter, a practicing ophthalmologist in Hartford, Connecticut and is affiliated with Hartford Hospital.  Dr. David Reichstein, an ocular oncologist, who studied at the renowned Wills Eye Hospital here from Tennessee Retina. Dr. Peter Hovland, who specializes in vitreoretinal disease & surgery, and ophthalmology, here from Colorado Retina.   At Aura, our mission is to develop a new class of oncology targeted therapies that deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. Second half of episode: Understanding Genetics Testing with Castle Biosciences Join Dr. Reichstein, Dr. Hovland, and Dr. Walter for a discussion on genetics in uveal melanoma. This session is brought to you by Castle Biosciences. Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. These tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions. They believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate, and can be improved by incorporating personalized genomic information.  

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Go online to PeerView.com/UTP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is essential for determining the best therapeutic approach for each patient. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from targeted therapies, and the list of relevant targets and matched therapies continues to expand, including in early-stage disease settings. Unfortunately, molecular testing rates remain woefully inadequate, and even when testing is performed, many patients are not receiving optimally matched targeted therapy based on their tumor type. This PeerView educational video based on a recent live event and developed in collaboration with the LUNGevity Foundation brings leading lung cancer experts together to go beyond the basics and help navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer. Expert discussions are framed with patient perspectives and illustrative case scenarios to highlight strategies for improving team-based collaboration, patient engagement, health equity, and biomarker-informed management plans to provide the best possible care to all patients. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC, Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC, Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials, considering biomarker status; current evidence and guidelines; multidisciplinary perspectives; and patient needs, values, and preferences, Implement multidisciplinary and patient-centric approaches to ensure timely and accurate diagnosis, appropriate biomarker testing, individualized treatment, and equitable care of all patients with NSCLC.

Russian forces have made new advances in eastern Ukraine - and are now close to encircling the strategic city of Severodonetsk.

Treatments for moderate-to-severe atopic dermatitis in children have made huge strides in recent months. Listen to Lawrence Eichenfield, MD, Emma Guttman-Yassky, MD, PhD, Candrice Heath, MD, and Minnelly Luu, MD discuss these advancements, what they mean for patients, and the importance of present and future research. This is a follow-up podcast to the https://pedraresearch.org/2020/09/25/2020-mod-severe-ad-ed/ (Emerging Therapies in the Treatment of Moderate-to-Severe Atopic Dermatitis in Children) educational series that aired in 2020. 

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

In this guru addition host Lindsay Berra talks with Mike Boyle about his practical approach to strength coaching and fitness lifestyle. Author of New Advances in Functional Training, Mike is the founder of Mike Boyle Strength and Conditioning and he has strong opinions about the right way to do things. Previously he served as the Head Strength and Conditioning Coach at Boston University with a focus on Hockey. He also served as the Strength and Conditioning Coach for the Boston Bruins of the NHL and for the 1998 US Women's Olympic Ice Hockey Team, Gold Medalists in Nagano. One of the foremost experts in the fields of Strength and Conditioning, Performance Enhancement and general fitness he talks about what it takes to be healthy in today's world where the odds are clearly stacked against us. See omnystudio.com/listener for privacy information.

New Advances in Brain Tumor Treatments and Trials with guest Dr. Zachary Corbin August 19, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

New Advances in Brain Tumor Treatments and Trials with guest Dr. Zachary Corbin August 19, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

In the past year, Google has made quite a few changes to advance its Ad Platform. We've already seen Standard Text Ads being replaced with the much meatier Expanded Text Ads and now, the latest addition is Responsive Search Ads. Responsive Search Ads display up to three headlines consisting of 30 characters each, simultaneously. They also display up to two lines of description, consisting of 90 characters each – giving your ads over 80% more real estate on the SERP. In addition, with these multiple ad elements, Google employs its machine-learning skills to identify which elements of your ads are most effective over time. In today's The Big Idea podcast, Francois Lubbe speaks Christina Clapp about the benefits of using Responsive Search Ads as an additional tool for multivariate testing, as well as highlighting some its potential drawbacks.

New Advances in Stem Cell Transplant with guest Stuart Seropian, MD March 4, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

New Advances in Stem Cell Transplant with guest Stuart Seropian, MD March 4, 2018 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Immunotherapy is one of the most exciting areas of new discoveries and treatments for different kinds of cancer. Understanding how the immune system works is opening the doors to developing new treatments that are changing the way we think about and treat cancer. On this episode, guest host Linda House is joined by Dr. Gerald Messerschmidt to talk about immunotherapy and its new advancements in recent years. Elizabeth Franklin also joins the program to discuss barriers and access to quality care for patients with cancer.